Back to Search
Start Over
A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Dec 21; Vol. 12, pp. 800723. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- The ongoing COVID-19 vaccine rollout is critical for reducing SARS-CoV-2 infections, hospitalizations, and deaths worldwide. Unfortunately, massive disparities exist in getting vaccines to vulnerable populations, including people living with HIV. Preliminary studies indicate that COVID-19 mRNA vaccines are safe and immunogenic in people living with HIV that are virally suppressed with potent antiretroviral therapy but may be less efficacious in immunocompromised individuals. This raises the concern that COVID-19 vaccines may be less effective in resource poor settings with limited access to antiretroviral therapy. Here, we evaluated the immunogenicity of a single dose COVID-19 replicon RNA vaccine expressing Spike protein (A.1) from SARS-CoV-2 (repRNA-CoV2S) in immunocompromised, SIV infected and immune competent, naïve pigtail macaques. Moderate vaccine-specific cellular Th1 T-cell responses and binding and neutralizing antibodies were induced by repRNA-CoV2S in SIV infected animals and naïve animals. Furthermore, vaccine immunogenicity was elicited even among the animals with the highest SIV viral burden or lowest peripheral CD4 counts prior to immunization. This study provides evidence that a SARS-CoV-2 repRNA vaccine could be employed to induce strong immunity against COVID-19 in HIV infected and other immunocompromised individuals.<br />Competing Interests: JE, JA, and DF have equity interest in HDT Bio. JE is a consultant for InBios. DF is a consultant for Gerson Lehrman Group, Orlance, Abacus Bioscience, Neoleukin Therapeutics. JE is a co-inventor on U.S. patent application no. 62/993,307 “Compositions and methods for delivery of RNA” pertaining to the LION formulation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 O’Connor, Erasmus, Randall, Archer, Lewis, Brown, Fredericks, Groenier, Iwayama, Ahrens, Garrison, Wangari, Guerriero and Fuller.)
- Subjects :
- Animals
Antibodies, Neutralizing blood
Antibodies, Viral blood
COVID-19 immunology
COVID-19 virology
COVID-19 Vaccines genetics
COVID-19 Vaccines immunology
Cells, Cultured
Disease Models, Animal
Host-Pathogen Interactions
Immunocompromised Host
Macaca nemestrina
Male
Simian Acquired Immunodeficiency Syndrome blood
Simian Acquired Immunodeficiency Syndrome virology
Simian Immunodeficiency Virus pathogenicity
Spike Glycoprotein, Coronavirus genetics
Spike Glycoprotein, Coronavirus immunology
Th1 Cells drug effects
Th1 Cells immunology
Th1 Cells virology
Time Factors
Vaccination
mRNA Vaccines genetics
mRNA Vaccines immunology
COVID-19 prevention & control
COVID-19 Vaccines administration & dosage
Immunity, Cellular drug effects
Immunity, Humoral drug effects
Immunogenicity, Vaccine
Simian Acquired Immunodeficiency Syndrome immunology
Simian Immunodeficiency Virus immunology
Spike Glycoprotein, Coronavirus administration & dosage
Vaccine Efficacy
mRNA Vaccines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 34992610
- Full Text :
- https://doi.org/10.3389/fimmu.2021.800723